March 4, 2021 -- Contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies held a ceremony on March 3 to celebrate the large-scale expansion of cell culture capacity at its production facility in Hillerød, Denmark.
The expansion project includes the addition of six 20,000-L bioreactors, which represents a doubling of the facility's bulk drug substance production capacity and the installation of fill/finish capability to support production of approximately 35 million units per year, Fujifilm Diosynth said in a statement.
Turning of the soil at Fujifilm Diosynth Biotechnologies in Denmark signals the start of expansion project. Image courtesy of Fujiflim Diosynth.
The revamp was made possible by a capital investment of 100 billion yen ($928 million U.S.) from parent company Fujifilm. Fujifilm Diosynth said that it is adding 300 staff in Denmark by the end of 2023 to support new activities.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
